Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 224Rectal Neoplasms 124Colonic Neoplasms 120Stomach Neoplasms 60Pancreatic Neoplasms 58Neoplasm Metastasis 48Lymphoma 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Leukemia 32Esophageal Neoplasms 32Neoplasms 31Burkitt Lymphoma 19Adenocarcinoma Of Esophagus 17Adenocarcinoma 17Carcinoma, Hepatocellular 13Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Unspecified Adult Solid Tumor, Protocol Specific 11Biliary Tract Neoplasms 11Lymphoma, Mantle-Cell 10Gallbladder Neoplasms 10Liver Neoplasms 9Osteosarcoma 8Lymphoma, Large-Cell, Immunoblastic 8Gastrointestinal Neoplasms 8Bile Duct Neoplasms 8Lymphoma, Follicular 7Dendritic Cell Sarcoma, Interdigitating 7Cholangiocarcinoma 7Leukemia, Myeloid, Acute 6

Interventions

Cyclophosphamide 2pembrolizumab 1napabucasin 1guadecitabine 1Sutures 1Surgical Instruments 1Pemetrexed 1Oxaliplatin 1Oviposition 1Ocoxin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Irinotecan 1Fluorouracil 1Drainage 1Colonoscopy 1Cetuximab 1Capecitabine 1Bevacizumab 15-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 15,10-methylenetetrahydrofolic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Rectal Diseases × Leucovorin × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡